Headquartered in St. Louis, Missouri, KV Pharmaceutical is a specialty pharmaceutical company with a focus on women’s healthcare. Through our operations subsidiary, Ther-Rx Corporation, we develop, distribute, and support a portfolio of pharmaceutical products that healthcare providers can prescribe with confidence, and pharmacists can dispense with trust. Ther-Rx’s employees are passionately committed to advancing the health of women across all the stages of her life. Click here to learn more about us.
|
Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%) for Prescribing
Single dose prescription treatment for vulvovaginal candidiasis
(yeast infections) now available on pharmacy shelves
St. Louis, January 24, 2013 – Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHA/KVPHB), and Perrigo Company (Nasdaq: PRGO; TASE) announced today that Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by Candida) in non-pregnant women1, is now available for prescribing. Gynazole-1 is available at major national and regional retail pharmacy chains across the country.
Ther-Rx has partnered with Perrigo (www.perrigo.com) to manufacture Gynazole-1. Perrigo is a leading manufacturer of prescription drugs in the U.S. market that has been inspected and approved by the U.S. Food and Drug Administration (FDA) as being in compliance with current Good Manufacturing Practice requirements to manufacture Gynazole-1.
Click here to view the full Company Statement.
|
|
|
|